In spite of increasing price pressure, the $9 billion global spine market is projected to see low-single-digit growth in the next few years. Driving growth are the pure-play spine companies targeting high-growth segments such as minimally invasive surgery, expandable interbody cases, cervical discs, and deformity.

OrthAlign has received 510(k) clearance for OrthAlign Plus, a palm-sized “smart” instrument designed to be a reliable and efficient alternative to expensive and bulky computer-assisted surgery systems.

The current technologies for diagnosing spinal disease don’t consistently deliver what’s required of any medical diagnostic: good predictive value, high specificity, sensitivity, validity, reproducibility, and safety. This is a gap that several young, innovative companies have set out to fill.

The current technologies for diagnosing spinal disease don’t consistently deliver what’s required of any medical diagnostic: good predictive value, high specificity, sensitivity, validity, reproducibility, and safety. This is a gap that several young, innovative companies have set out to fill.